Promatix Inc. develops a multi-omics platform that utilizes proteomic analysis of membrane proteins to identify optimal combinations of cancer surface markers for bispecific antibody drug conjugates (ADCs). This approach enhances tumor selectivity and reduces off-target toxicity, addressing the challenge of effective cancer treatment across various tumor types.
Funding
Funding not disclosed
Founders
Product
Problem
Conventional cancer therapies often lack the specificity needed to target tumor cells effectively, leading to off-target toxicity and limiting the range of treatable cancers. Traditional antibody-drug conjugates (ADCs) may bind to healthy cells expressing the target antigen, resulting in adverse side effects and reduced therapeutic efficacy.
Solution
Promatix Biosciences is developing a multi-omics platform to identify optimal combinations of cancer surface markers for cis-bispecific antibody drug conjugates (ADCs). By analyzing the surfaceome—all membrane proteins—in both normal and cancerous tissues, Promatix identifies unique pairings of target antigens present on tumor cells but absent or minimally expressed on healthy cells. This approach enhances tumor selectivity and reduces off-target toxicity by exploiting hybrid avidity, where bispecific antibodies bind more strongly to cells expressing both target markers. The platform facilitates the rational design of enhanced targeting agents, including functional inhibitors, radio-ligands, and T cell engagers, expanding the range of targets and indications for ADCs.
Target Audience
The primary target audience includes pharmaceutical companies and research institutions focused on oncology drug development, particularly those working with antibody-drug conjugates and bispecific antibodies.
Features
- TxPro: A cancer proteomics database with comprehensive coverage of surface proteins across a wide range of cancer types.
- CipherPro: A proprietary set of algorithms for systematic mining of target antigen pairs to enhance tumor specificity and therapeutic index.
- AviPro: A proprietary in silico system for fine-tuning bispecific antibody affinities to maximize the therapeutic index.
- BiPro: A rapid functional analysis pipeline based on a modular molecular framework to support selection of bispecific lead assets.
- Portfolio of bispecific antibodies across fourteen cancer types (solid tumors), including novel pairings for known targets and completely novel bispecific combinations.
- Flexible platform enabling the rational design of enhanced targeting agents as functional inhibitors, radio-ligands and T cell engagers.